Featured Stories
APPROVED IN EU
EU Approves Duvyzat for the Treatment of Duchenne Muscular Dystrophy
Italfarmaco is now working closely with national authorities and distribution partners to facilitate timely access to Duvyzat across the EU.
Read More
Interview with our CEO Maja Strnad Cestar for Bulgarian weekly Kapital
We Bring Innovative Therapies Closer to Bulgarian Patients
We have been present in the Bulgarian market since 2017 through our local company, Medis Pharma Bulgaria, offering a broad and diversified portfolio.
Read More
Positive CHMP Opinion
CHMP recommends EU approval for Duvyzat to treat Duchenne muscular dystrophy
If approved by the European Commission, Duvyzat will be available for individuals with DMD aged six years and older who are able to walk.
Read More
New treatment of Duchenne muscular dystrophy
Italfarmaco and Medis Announce Exclusive Distribution Agreement for Givinostat in 17 Central and Eastern European Countries including the Baltic States
Givinostat has already received regulatory approval in the US and UK, with an evaluation ongoing by the European Medicines Agency (EMA).
Read More
Celebration of Outstanding research achievements
Winners of the 11th International Medis Awards for Medical Research announced
The President of the Republic of Slovenia Nataša Pirc Musar, PhD, was the honorary speaker at the ceremony.
Read More
Recognition for Excellence in the Workplace
Medis Wins the Prestigious German Economy Award 2024/25
The company Medis has been awarded the German Economy Award 2024/25 in the category "Excellent Employer".
Read More